Epidemiology of cardiomyopathies in children and adolescents: A retrospective study over the last 10 years

Cardiology in the Young

Volumn 12, Issue 3, 2002, Pages 253-259

  Malčić, Ivan ^a   Jelušić, Marija ^a   Kniewald, Hrvoje ^a   Barišić, Nina ^a   Jelašić, Dražen ^a   Božikov, Jadranka ^b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cardiomyopathies; Childhood; Epidemiology

Indexed keywords

ADOLESCENT; ARTICLE; CARDIOMYOPATHY; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; NEUROMUSCULAR DISEASE; RESTRICTIVE CARDIOMYOPATHY; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION; ADULT; AGE DISTRIBUTION; CROATIA; FEMALE; INFANT; MALE; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SEX RATIO; STATISTICS; TIME; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; CROATIA; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INFANT; INFANT, NEWBORN; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TIME FACTORS;

EID: 0036579977     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1047951102000550     Document Type: Article

References (44)

1. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.
2. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, Tikanoja T, Paavilainen T, Simell O. Epidemiology of idiopathic cardiomyopathies in children and adolescents. Am J Epidemiol 1997; 146: 385-393.
3. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population-based study in Olmested County, Minnesota, 1975-1984. Circulation 1989; 80: 564-572.
4. Bagger JP, Baandrup U, Rasmussen K, Moller M, Vesterlund T. Cardiomyopathy in western Denmark. Br Heart J 1984; 52: 327-331.
5. Schwartz K, Mercadier JJ. Molecular and cellular biology of heart failure. Curr Opin Cardiol 1996; 11: 227-236.
6. Pathak SK, Kukreja RC, Hess ML. Molecular pathology of dilated cardiomyopathies. Curr Probl Cardiol 1996; 21: 99-144.
7. Mestroni L, Rocco C, Vatta M, Miocic S, Giacca M. Advances in molecular genetics of dilated cardiomyopathy. Cardiol Clin 1998; 16: 611-621.
8. New York Heart Criteria Committee: Nomenclature and Criteria for Diagnosis of Disease of the Heart and Great Vessels, 8th edn. Little, Brown and Co, 1979.
9. The Normal Echocardiographic Examination. In: Goldberg SJ, Allen HD, Sahn DJ. Pediatric and Adolescent Echocardiography, 2nd edn. Year Book Medical Publishers, Inc. Chicago, London, 1980, pp 61-126.
10. Maron BJ. Hypertrophic cardiomyopathy. In: Emmanouilides GC, Riemenschneider TA, Gutgesell HP (eds). Heart Disease in Infants, Children, and Adolescents, 5th edn. Williams & Wilkins, Baltimore, 1995, pp 1337-1361.
11. Dubourg O, Bourddaris JP. Doppler echocardiographic investigation of cardiomyopathies. Arch Mal Coeur Vaiss 1996; 2: 39-45.
12. Dubourg O, Pellerin D, Coisne D, Beauvais F, Jondeau G, Bourdarias JP. The echocardiographic examination in adult cardiomyopathy. Arch Mal Coeur Vaiss 1998; 91: 35-42.
13. Chan DP, Allen HD. Dilated congestive cardiomyopathy. In: Emmanouilides GC, Riemenschneider TA, Gutgesell HP (eds). Heart Disease in Infants, Children, and Adolescents, 5th edn. Williams & Wilkins, Baltimore, 1995, pp 1365-1381.
14. Langlard JM. Restrictive cardiomyopathy. Arch Mal Coeur Vaiss 1998; 91: 59-64.
15. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619-624.
16. Vosberg HP, Uhl WK, Schulz O, Trojani A, Schlepper M, McKeown P, Nauheim B. Molecular diagnosis of causes of dominantly hypertrophic cardiomyopathies. In: Sauer U, Schumacher G. Herzfehler und Genetik. Wissenschaftliche Verlagsgesellschaft mbH. Stuttgart, 1999, pp 237-259.
17. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999; 281: 1746-1752.
18. Dausse E, Komajda M, Fetler L, et al. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and indentification of a hot spot for mutations in the β-myosin heavy chain gene. J Clin Invest 1993; 92: 2807-2813.
19. Burch M, Blair E. The inheritance of hypertrophic cardiomyopathy. Pediatr Cardiol 1999; 20: 313-316.
20. Mogensen J, Klausen IC, Pedersen AK, et al. Alfa-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103: 39-43.
21. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 1999; 262: 411-417.
22. Seidman CE, Seidman JG. Molecular genetic studies of familial hypertrophie cardiomyopathy. Basic Res Cardiol 1998; 93 (Suppl 3): 13-16.
23. Baschinski LL, Roberts R. New theories. Causes of dilated Cardiomyopathy. Cardiol Clin 1998; 16: 603-610.
24. Watkins H, Conner D, Thierfelder L, et al. Mutation in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11: 434-437.
25. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. Circulation 1998; 98: 1460-1471.
26. Anan R, Greve G, Thierfelder L, et al. Prognostic impications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93: 280-285.
27. Charron P, Dubourg O, Desnos M, et al. Genotype-phenotype correlations in familial cardiomyopathy. A comparison between mutations in the cardiac protein-C and beta-myosin haevy chain genes. Eur Heart J 1998; 19: 139-145.
28. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and indetical β-heavy chain gene mutations. Circulation 1994; 89: 22-32.
29. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1995; 92: 38-64.
30. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998; 83: 580-593.
31. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation 1992; 86: 345-352.
32. Hayes DL. Evolving indications for permanent pacing. Am J Cardiol 1999; 83: 161D-165D.
33. Symanski JD, Nishimura RA. The use of pacemakers in the treatment of cardiomyopathies. Curr Probl Cardiol 1996; 21: 385-444.
34. Wu AH, Das SK. Sudden death in dilated cardiomyopathy. Clin Cardiol 1999; 22: 267-272.
35. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for prevention of sudden death in patients with hypertrophie cardiomyopathy. N Engl J Med 2000; 342: 365-373.
36. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.
37. Sadoul N, de Chillou C, Aliot E, McKenna WJ. Evaluation of the risk of sudden death in hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss 1999; 92: 65-73.
38. Fananapazir L, McAreaveay D. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol 1997; 20: 478-501.
39. Fananapazir L, Chang AC, Epstein SE, McAreaveay D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation 1992; 86: 730-740.
40. Schulte HD, Gramsch-Zabel H, Schwartzkopff B, Gams E. Hypertrophic cardiomyopathy. Surgical versus drug therapy. Z Kardiol 1999; 88: 163-172.
41. Thierfelder L. Genetics of dilated cardiomyopathy. Med Klin 1998; 93: 210-214.
42. Ferlini A, Sewry C, Melis MA, Mateddu A, Mutoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999; 9: 339-346.
43. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998; 10: 131-139.
44. Thierfelder L. Genetic screening of cardiomyopathies. Z Kardiol 2000; 89: 638-640.